Recombinant Human SLAMF7 Protein, His-tagged

• Cat.No.: SLAMF7-121H
• Product Overview: Recombinant Human SLAMF7 Protein with His tag was expressed in E. coli.

Specification

• Description: CRACC/SLAMF7/CD319 (also known as CS1) is a member of the signaling lymphocytic activation molecule (SLAM) family. It is a single-pass type l transmembrane glycoprotein expressed on NK cells, subsets of mature dendritic cells, activated B and T lymphocytes, but not in promyelocytic B or T cell lines. Expression of this protein has been detected in the spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung, and trachea. Homophilic interactions of CRACC/SLAMF7/CD319 modulate the activity and differentiation of immune cells. CRACC/SLAMF7/CD319 may function as an inhibitory or activating receptor in immune cells depending on cellular context and availability of adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. In the presence of SH2D1B/EAT-2, CRACC/SLAMF7/CD319 activates NK cells and B cells. T cells lack SH2D1B/EAT-2 expression, and therefore CRACC/SLAMF7/CD319 acts as an inhibitory receptor. In LPS-activated monocytes, CRACC/SLAMF7/CD319 negatively regulates production of proinflammatory cytokines. CRACC/SLAMF7/CD319 is upregulated in multiple myeloma and is implicated in the uncontrolled proliferation of these cells, and thus has become the target for therapeutic intervention. Seven isoforms of CRACC/SLAMF7/CD319 produced by alternative splicing have been identified.
• Source: E. coli
• Species: Human
• Tag: His
• Molecular Mass: ~25 kDa
• AA Sequence: SGPVKELVGSVGGAVTFPLKSKVKQ VDSIVWTFNTTPLVTIQPEGGTIIV TQNRNRERVDFPDGGYSLKLSKLKK NDSGIYYVGIYSSSLQQPSTQEYVL HVYEHLSKPKVTMGLQSNKNGTCVT NLTCCMEHGEEDVIYTWKALGQAAN ESHNGSILPISWRWGESDMTFICVA RNPVSRNFSSPILARKLCEGAADDP DSSM
• Purity: Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE).
• Notes: For research use only, not for use in diagnostic procedure.
• Storage: Store at 4 centigrade short term. Aliquot and store at -20 centigrade long term. Avoid freeze-thaw cycles.
• Concentration: ≥0.5 mg/mL
• Storage Buffer: PBS, 4M Urea, pH7.4

Gene Information

• Gene Name: SLAMF7 SLAM family member 7 [ Homo sapiens (human) ]
• Official Symbol: SLAMF7
• Synonyms: SLAMF7; SLAM family member 7; 19A; CD319; CRACC; CS1; protein 19A; CD2 subset 1; 19A24 protein; membrane protein FOAP-12; CD2-like receptor activating cytotoxic cells; CD2-like receptor-activating cytotoxic cells; novel LY9 (lymphocyte antigen 9) like protein
• Gene ID: 57823
• mRNA Refseq: NM_021181
• Protein Refseq: NP_067004
• MIM: 606625
• UniProt ID: Q9NQ25

Reviews

07/28/2023

It has a high solubility and can be easily prepared at the desired concentration.

07/26/2021

It was found to be well active and could effectively perform the required biological activity experiments.

04/15/2020

It was observed that SLAMF7 had good crystallinity, which was conducive to crystallography research.

Q&As

What is the mechanism by which SLAMF7 protein regulates immune responses?

SLAMF7 protein is involved in regulating immune cell activation, proliferation, and transmission of background signals by binding to activating ligands, such as CD319, thereby influencing the immune response.

What is the potential of combining SLAMF7 protein with immunotherapy?

By combining with immunotherapy, such as anti-PD-1 antibodies, the immune response can be further enhanced and the anti-tumor effect can be improved. The study of SLAMF7 protein provides a new direction for the development of combinatorial therapeutic strategies.

In which tissues or cells is SLAMF7 protein expressed?

This protein is mainly expressed in the immune system, including immune cells such as plasma cells, NK cells, and activated T cells.

Does the SLAMF7 protein have a similar role in other types of cancer?

The role of SLAMF7 protein in other types of cancer is unclear, and further research is needed to determine its potential role in other cancers.

Does SLAMF7 protein have potential in the treatment of multiple myeloma?

Yes, the SLAMF7 protein has been shown to be a potential therapeutic target. A monoclonal antibody drug targeting SLAMF7 protein (Elotuzumab) has been developed for the treatment of multiple myeloma.

What is the function of SLAMF7 protein in multiple myeloma?

SLAMF7 protein interacts with NK cells in multiple myeloma and plays a role in inhibiting and controlling tumor growth by activating the anti-tumor activity of NK cells.